PD Dr med Arnoud Templeton
Behandlung des fortgeschrittenen Prostatakarzinoms - eine interdisziplinäre Empfehlung
Omlin A, Zwahlen D, Wyler S, Wild D, Templeton A, Stenner F, Schmid H, Roggero E, Rentsch C, Nitzsche E, Kueng M, Jochum W, Gillessen Sommer S, Eberli D, Beyer J, Spahn M, Cathomas R. Behandlung des fortgeschrittenen Prostatakarzinoms - eine interdisziplinäre Empfehlung. Schweiz Rundschau Med (PRAXIS) 2018; 107:1043-51.
01.01.2018Behandlung des fortgeschrittenen Prostatakarzinoms - eine interdisziplinäre Empfehlung
01.01.2018Schweiz Rundschau Med (PRAXIS) 2018; 107:1043-51
Omlin Aurelius, Zwahlen D, Wyler S, Wild D, Templeton Arnoud, Stenner F, Schmid Hans-Peter, Roggero E, Rentsch CA, Nitzsche E, Kueng M, Jochum W, Gillessen Sommer Silke, Eberli D, Beyer J, Spahn M, Cathomas R
Circulating DNA and survival in solid tumors
Ocana A, Pandiella A, Andrés-Pretel F, Seruga B, Corrales-Sanchez V, Serrano-Heras G, Gascon-Escribano M, Vera-Badillo F, Templeton A, Garcia-Olmo D, Diez-Gonzalez L, Amir E. Circulating DNA and survival in solid tumors. Cancer Epidemiol Biomarkers Prev 2015
24.11.2015Circulating DNA and survival in solid tumors
24.11.2015Cancer Epidemiol Biomarkers Prev 2015
Ocana Alberto, Pandiella Atanasio, Andrés-Pretel Fernando, Seruga Bostjan, Corrales-Sanchez Verónica, Serrano-Heras Gemma, Gascon-Escribano Maria José, Vera-Badillo Francisco, Templeton Arnoud, Garcia-Olmo Dolores C, Diez-Gonzalez Laura, Amir Eitan
Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials
AlHashem H, Al-Mubarak M, Vera-Badillo F, Templeton A, Ocana A, Šeruga B, Amir E. Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. Clin Oncol (R Coll Radiol) 2015
02.11.2015Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials
02.11.2015Clin Oncol (R Coll Radiol) 2015
AlHashem H Y, Al-Mubarak M, Vera-Badillo F E, Templeton Arnoud, Ocana A, Šeruga B, Amir E
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
Sonpavde G, Pond G, Templeton A, Fandi A, Tombal B, Rosenthal M, Armstrong A, Petrylak D. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. Eur Urol 2015
20.10.2015Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
20.10.2015Eur Urol 2015
Sonpavde Guru, Pond Gregory R, Templeton Arnoud, Fandi Abderrahim, Tombal Bertrand, Rosenthal Mark, Armstrong Andrew J, Petrylak Daniel P
Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses
Ocana A, Pandiella A, Niraula S, Seruga B, Vera-Badillo F, Templeton A, Gascón-Escribano M, Srikanthan A, Corrales-Sanchez V, Diez-Gonzalez L, Ethier J, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget 2015
04.10.2015Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses
04.10.2015Oncotarget 2015
Ocana Alberto, Pandiella Atanasio, Niraula Saroj, Seruga Bostjan, Vera-Badillo Francisco, Templeton Arnoud, Gascón-Escribano María J, Srikanthan Amirrtha, Corrales-Sanchez Verónica, Diez-Gonzalez Laura, Ethier Josee-Lyne, Amir Eitan
Primum non nocere
Templeton A, Šeruga B. Primum non nocere. Ann Oncol 2015; 26:2197-8.
13.07.2015Primum non nocere
13.07.2015Ann Oncol 2015; 26:2197-8
Templeton Arnoud, Šeruga B
Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer
Vera-Badillo F, Tannock I, Bedard P, Goldstein R, Seruga B, Templeton A, Ocana A, Kuruzar G, Chang M, Amir E. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. J Clin Pathol 2015
15.06.2015Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer
15.06.2015J Clin Pathol 2015
Vera-Badillo Francisco E, Tannock Ian F, Bedard Philippe L, Goldstein Robyn, Seruga Bostjan, Templeton Arnoud, Ocana Alberto, Kuruzar Gordana, Chang Martin C, Amir Eitan
Influence of censoring on conclusions of trials for women with metastatic breast cancer
Templeton A, Ace O, Amir E, Vera-Badillo F, Ocana A, Pond G, Tannock I. Influence of censoring on conclusions of trials for women with metastatic breast cancer. Eur J Cancer 2015
26.02.2015Influence of censoring on conclusions of trials for women with metastatic breast cancer
26.02.2015Eur J Cancer 2015
Templeton Arnoud, Ace Olga, Amir Eitan, Vera-Badillo Francisco, Ocana Alberto, Pond Gregory R, Tannock Ian F
Möglichkeiten und Grenzen der Komplementärmedizin in der Onkologie
Schlaeppi M, Templeton A. Möglichkeiten und Grenzen der Komplementärmedizin in der Onkologie. Onkologische Pharmazie 2015; 1:46-50.
01.01.2015Möglichkeiten und Grenzen der Komplementärmedizin in der Onkologie
01.01.2015Onkologische Pharmazie 2015; 1:46-50
Schlaeppi Marc, Templeton Arnoud
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
Lorente D, Sartor O, Su Z, Shen L, Bahl A, Ferraldeschi R, Bianchini D, Zafeiriou Z, Templeton A, Mateo J, de Bono J. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol 2014
23.12.2014Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
23.12.2014Ann Oncol 2014
Lorente D, Sartor O, Su Z, Shen L, Bahl A, Ferraldeschi R, Bianchini D, Zafeiriou Z, Templeton Arnoud, Mateo J, de Bono J S
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†
van Soest R, Tannock I, Eisenberger M, Rosenthal M, Tombal B, Amir E, Sonpavde G, Mercier F, Vera-Badillo F, Templeton A, De Wit R. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†. Ann Oncol 2014
15.12.2014Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials†
15.12.2014Ann Oncol 2014
van Soest R J, Tannock I F, Eisenberger M A, Rosenthal M, Tombal B, Amir E, Sonpavde G, Mercier F, Vera-Badillo F E, Templeton Arnoud, De Wit R
Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies
Kroeger N, Smoragiewicz M, Lee J, Rini B, Vaishampayan U, Wood L, Beuselinck B, Donskov F, Choueiri T, Bernstein E, Knox J, Templeton A, Pantuck A, Wells J, Lawrence N, Broom R, Kim J, Srinivas S, Yim J, Bjarnason G, Heng D. Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. Eur Urol 2014
15.12.2014Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies
15.12.2014Eur Urol 2014
Kroeger Nils, Smoragiewicz Martin, Lee Jae, Rini Brian I, Vaishampayan Ulka N, Wood Lori A, Beuselinck Benoit, Donskov Frede, Choueiri Toni K, Bernstein Ezra, Knox Jennifer, Templeton Arnoud, Pantuck Allan J, Wells J Connor, Lawrence Nicola, Broom Reuben, Kim Jenny J, Srinivas Sandy, Yim Jessica, Bjarnason Georg A, Heng Daniel Y
Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis
Rocha P, Morgan C, Templeton A, Pond G, Naik G, Sonpavde G. Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis. Oncol Res Treat 2014; 37:772-6.
20.11.2014Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis
20.11.2014Oncol Res Treat 2014; 37:772-6
Rocha Pedro, Morgan Charity J, Templeton Arnoud, Pond Gregory R, Naik Gurudatta, Sonpavde Guru
Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs
Tibau A, Barnadas A, Seruga B, Ocana A, Templeton A, Vera-Badillo F, Ethier J, Srikanthan A, Bedard P, Amir E. Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs. J Clin Oncol 2014; 33:100-6.
10.11.2014Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs
10.11.2014J Clin Oncol 2014; 33:100-6
Tibau Ariadna, Barnadas Agustí, Seruga Bostjan, Ocana Alberto, Templeton Arnoud, Vera-Badillo Francisco E, Ethier Josee-Lyne, Srikanthan Amirrtha, Bedard Philippe L, Amir Eitan
Use and misuse of waterfall plots
Shao T, Shoushtari H, Sinaei M, Kim T, Margolis M, McNamara M, Vera-Badillo F, Jang R, Templeton A, Wang L, Tannock I. Use and misuse of waterfall plots. J Natl Cancer Inst 2014; 106
29.10.2014Use and misuse of waterfall plots
29.10.2014J Natl Cancer Inst 2014; 106
Shao Tiffany, Shoushtari Hassan, Sinaei Mehrdad, Kim Tae Kyoung, Margolis Myles, McNamara Mairead G, Vera-Badillo Francisco W, Jang Raymond, Templeton Arnoud, Wang Lisa, Tannock Ian F
Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer
Leibowitz-Amit R, Templeton A, Alibhai S, Knox J, Sridhar S, Tannock I, Joshua A. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. J Geriatr Oncol 2014; 6:23-8.
07.10.2014Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer
07.10.2014J Geriatr Oncol 2014; 6:23-8
Leibowitz-Amit Raya, Templeton Arnoud, Alibhai Shabbir M, Knox Jennifer J, Sridhar Srikala S, Tannock Ian F, Joshua Anthony M
Komplementärmedizin in der Onkologie
Schlaeppi M, Templeton A. Komplementärmedizin in der Onkologie - Was der Grundversorger wissen sollte. Swiss Medical Forum 2014; 14:689-693.
08.09.2014Komplementärmedizin in der Onkologie
08.09.2014Swiss Medical Forum 2014; 14:689-693
Schlaeppi Marc, Templeton Arnoud
Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis
Templeton A, Diez-Gonzalez L, Ace O, Vera-Badillo F, Seruga B, Jordán J, Amir E, Pandiella A, Ocana A. Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. Cancer Treat Rev 2014; 40:1048-55.
03.09.2014Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis
03.09.2014Cancer Treat Rev 2014; 40:1048-55
Templeton Arnoud, Diez-Gonzalez Laura, Ace Olga, Vera-Badillo Francisco, Seruga Bostjan, Jordán Joaquín, Amir Eitan, Pandiella Atanasio, Ocana Alberto
Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone
Leibowitz-Amit R, Alimohamed N, Vera-Badillo F, Seah J, Templeton A, Knox J, Tannock I, Sridhar S, Joshua A. Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone. Prostate 2014; 74:1462-4.
11.08.2014Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone
11.08.2014Prostate 2014; 74:1462-4
Leibowitz-Amit Raya, Alimohamed Nimira, Vera-Badillo Francisco E, Seah Jo-An, Templeton Arnoud, Knox Jennifer J, Tannock Ian F, Sridhar Srikala S, Joshua Anthony M
Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment
Vera-Badillo F, Ocana A, Templeton A, Tibau A, Amir E, Tannock I. Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment. J Clin Oncol 2014; 32:3197.
04.08.2014Raising concern about the American Society of Clinical Oncology conflict of interest policy amendment
04.08.2014J Clin Oncol 2014; 32:3197
Vera-Badillo Francisco E, Ocana Alberto, Templeton Arnoud, Tibau Ariadna, Amir Eitan, Tannock Ian F